Tasman Therapeutics, Inc. is a US affiliate of New Zealand-based Douglas Pharmaceuticals Ltd with a pipeline developing novel treatments for mood disorders. The most advanced asset is R-107, a proprietary ketamine oral dose in Phase 3 studies as a therapy for patients with hard-to-treat depression.  

Douglas Pharmaceuticals develops and supplies generic and repurposed medicines to the US, EU and global markets.  R-107 is manufactured at its US FDA inspected plant in Auckland, New Zealand.

Tasman Therapeutics

Org chart

Teams

Offices

Tasman Therapeutics

Org chart

Teams

Offices

Related companies